Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Introductory Module
Manage episode 363402888 series 3381434
Valid until: 15-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-fine-print-the-who-when-and-what-to-do-about-aria-in-patients-with-alzheimers-disease/14848/
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This six-part series features distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This first activity focuses on the rise of amyloid-targeting DMT and the subsequent key features of ARIA that impact all specialties.=